MEKanistic Therapeutics
www.mekanistic.comLed by cancer research pioneers, MEKanistic is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window by inhibiting compensatory resistance pathways at the same time, avoiding inherent toxicity challenges of multi-compound treatments.
Read more
Led by cancer research pioneers, MEKanistic is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window by inhibiting compensatory resistance pathways at the same time, avoiding inherent toxicity challenges of multi-compound treatments.
Read more
Country
State
Minnesota
City (Headquarters)
Minneapolis
Industry
Employees
1-10
Founded
2022
Social
Employees statistics
View all employeesPotential Decision Makers
Co - Founder and Chief Security Officer
Email ****** @****.comPhone (***) ****-****Co - Founder
Email ****** @****.comPhone (***) ****-****Chief Operations Officer
Email ****** @****.comPhone (***) ****-****Chief Executive Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(16)
We'll help you understand if Lusha can solve your business needs.
